Healthcare
Professionals

Gamida Cell is developing next-generation cell therapies with curative potential for patients with cancer and other serious diseases. We are committed to supporting healthcare professionals who care for patients and share our goal of improving clinical outcomes.

Clinical Trials

Gamida Cell’s clinical development candidates, omidubicel and GDA-201, are designed to address areas of significant medical need. Read more about ongoing clinical trials of these investigative therapies below. For more information or questions, please contact us.

Omidubicel and GDA-201 are investigational therapies and their safety and efficacy have not been evaluated by the U.S. Food and Drug Administration or any other health authority.

Contact Us

Omidubicel for hematologic malignancies

Read More

Omidubicel is a NAM-enabled stem cell therapy candidate under development as a potential life-saving allogeneic hematopoietic stem cell (bone marrow) transplant solution for patients with hematologic malignancies (blood cancers). Omidubicel is the first bone marrow transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has also received Orphan Drug Designation in the U.S. and EU.

Omidubicel has been studied in an international, multi-center, randomized Phase 3 clinical study evaluating its the safety and efficacy compared to standard umbilical cord blood transplant.

  • The study achieved its primary endpoint (p<0.001). In the intent-to-treat analysis, median time to neutrophil engraftment was 12 days for patients receiving omidubicel (95% CI: 10-15 days) compared to 22 days for the comparator group (95% CI: 19-25 days).
  • Omidubicel was generally well tolerated. Among patients who were transplanted per protocol, rates of acute and chronic graft-versus host disease were similar and cumulative incidence of infections was significantly smaller in omidubicel compared to controls for both viral infections and bacterial or invasive fungal infections.
  • The study also met all three of its secondary endpoints, improving platelet engraftment, and reductions in infections and hospitalizations, which are key measures for success for bone marrow transplant.

The Phase 3 data also show that during the first 100 days of treatment, omidubicel-treated patients had significantly shorter durations of hospitalization, intensive care unit time, consultant visits, procedures, and transfusions than the control arm. These data provide further evidence of the clinical benefit associated with the more rapid hematopoietic recovery in patients treated with omidubicel and the corresponding reduction in healthcare resource utilization.

Full safety and efficacy data from this Phase 3 study have been published in Blood.

On August 1, the U.S. Food and Drug Administration accepted for filing the Company’s Biologics License Application for omidubicel for the treatment of patients with blood cancers in need of an allogenic hematopoietic stem cell transplant. The FDA granted Priority Review for the BLA and has set a target action date of January 30, 2023.

Omidubicel for severe aplastic anemia

Read More

Omidubicel is also being evaluated in an ongoing investigator-sponsored Phase 1/2 study in patients with severe aplastic anemia. For more information about the study, please visit www.clinicaltrials.gov (NCT03173937).

GDA-201

Read More

GDA-201 is a NAM-enabled NK cell therapy candidate. The study of the cryopreserved formulation of GDA-201 is currently open to enrollment at Henry Ford Cancer Institute (Detroit, MI) and the Masonic Cancer Center at the University of Minnesota, and additional sites will be added in the coming months. The Phase 1 portion of the study is designed to evaluate the safety of GDA-201 in patients with follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL)/high grade B-cell lymphoma (HGBCL), marginal zone lymphoma or mantle cell lymphoma. The Phase 2 expansion phase is designed to evaluate the safety and efficacy of GDA-201 in two patient cohorts, FL and DLBCL/HGBCL. The study will include patients who have relapsed or refractory lymphoma after at least two prior treatments. For more information about the study, please visit www.clinicaltrials.gov (NCT03019666).

GDA-201 has been evaluated in a Phase 1 investigator-led study in patients with refractory non-Hodgkin lymphoma (NHL) and multiple myeloma, demonstrating that GDA-201 generally was well tolerated in 35 patients. Of the 19 patients with NHL, 13 complete responses and one partial response were observed (CRR = 68%, ORR = 74%). No dose-limiting toxicities were observed.

Two-year follow up data in the same Phase 1 study demonstrated an overall survival rate of 78% at two years, with a median duration response of 16 months (Bachanova, et al. ASH 2021. Abstract #3854).

GRANTS & SPONSORSHIPS

Gamida Cell is proud to work with the scientific community to advance research that aligns with our mission of delivering curative new treatments for patients with cancer and other serious diseases. For more information about Gamida Cell medical education grants and sponsorships, please contact us.

Contact Us